Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global specialty pharmaceuticals business, announces that upon completion earlier today of the acquisition of Link Healthcare Private Limited ("Link") (the "Acquisition") (see separate announcement), John Bacon joined the Group as a Non-Executive Director. Johannes Willemse will act as John Bacon’s alternate on the Clinigen board (the “Board”).
Mr Bacon founded Link in 1997 thereby pioneering the supply of specialist pharmaceuticals in the Australian market. He served as Executive Chairman of Link before its acquisition by Clinigen. Prior to forming Link, John held senior positions in the pharmaceutical industry across the Asia-Pacific region.
Mr Willemse has over 25 years of experience in the pharmaceutical industry. He served as Chief Executive Officer of Link prior to its acquisition by Clinigen.
Mr Bacon holds 930,767 ordinary shares of 0.1p each in Clinigen. Mr Willemse does not hold any shares in Clinigen. However, Mr Willemse is beneficially interested in Vector Pharma Holdings Private Limited which itself holds 2,113,835 ordinary shares of 0.1p each in Clinigen. Both Mr Bacon and Vector Pharma Holdings Private Limited received their holdings in Clinigen today as part consideration for their interests in Link.
Peter Allen, Chairman, Clinigen, said: “On behalf of the Board, I welcome John to the team and I am pleased that Johannes has agreed to act as his alternate. Our strategic acquisition of Link has strengthened both Clinigen’s international distribution network across the AAA region - Asia, Africa and Australasia - as well as our management team. Together, we can better meet the growing demand for much needed, but not always licensed, medicines across the world.”
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. John Middleton Bacon, aged 57, has been a director of the following companies during the five years preceding the date of this announcement:
|Current directorship||Past directorship|
|Anggatha Pty ltd||Link Healthcare Private Limited|
|Ingenia Developments Pty Ltd||Link Healthcare Singapore Pte Ltd|
|The Medical Stockings Company||Link Healthcare Pty Ltd|
|JM & LJ Investments Pty Ltd||Link Healthcare Pty Ltd|
|JM & LJ Superannuation Management Pty Ltd||Link Holding 2 Pty Ltd|
|Ingeneia Pty Ltd||Link Medical Products Pty Ltd|
|Link Pharmaceuticals Ltd|
|Medical Stockings Pty Ltd|
|Debra Australia Limited|
|Split It PTY LTD|
|Whey To Go Pty Ltd|
|Flordis Herbal Medicines|
|Royal Prince Alfred Yacht Club|
Johannes Willemse, aged 47, currently holds director positions in the following companies:
Link Healthcare Private Limited
Link Healthcare Hong Kong Ltd
Link Healthcare Singapore Pte Ltd
Link Healthcare KK
Link Pharmaceutical KK
Link Healthcare Pty Ltd
Link Medical Products Pty Ltd
Link Healthcare SDN. BHD.
Link Healthcare Pty Ltd (trading as Equity Pharma Holdings)
Homemed Pty Ltd
Equity Pharmaceuticals Pty Ltd
Equity Medical Technologies Pty Ltd
Equipharm Specialized Distribution Pty Ltd
Novagen Pharma Pty Ltd
Plurilinx (Pty) Ltd
Chloromix (Pty) Ltd
Mr Willemse was also, within the last five years, a director of Equity Dental (Pty) Limited.
There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.
Clinigen Group plc
Peter George, Group Chief Executive Officer
Shaun Chilton, Group Deputy Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Tel: +44 (0) 1283 495010
Numis Securities Limited
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard (Corporate Broking)
Tel: +44 (0) 20 7260 1000
Peel Hunt LLP
James Steel/Jock Maxwell Macdonald
Tel: +44 (0) 20 7418 8900
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow
Tel: +44 (0) 20 7457 2020
Notes to Editors
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time. The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; Clinigen CTS manages the supply of commercial medicines for clinical trials; Idis Managed Access runs early access programs for Clinigen’s own and other companies' portfolios; Idis Global Access works directly with healthcare providers to enable ethical compliant access to unlicensed medicines and Clinigen SP acquires and markets our own portfolio of hospital only niche medicines.
Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need.
For more information, please visit www.clinigengroup.com.